Opinion|Videos|September 30, 2024
Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying
Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on the risk stratification tools IPSS-M and if you have adapted using this stratification tool in your practice.
- What do you are share to your patients in terms of prognosis for those with lower-risk MDS?
- What are some current challenges for treating lower-risk MDS?
Advertisement
Related to this article
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
3
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
4
QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC
5